COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,704 Articles (22,913 medRxiv, 8,791 bioRxiv)

Most recent first Previous |  Page 586: Articles 5851-5860  | Next

Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai older adults
Assantachai, P., Niyomnaitham, S., Chatthanawaree, W., Intalapaporn, S., Muangpaisan, W., Phannarus, H., Saichompoo, R. B., Sura-amonrattana, U., Wongprompitak, P., Toh, Z. Q., Licciardi, P. V., Srisutthisamphan, K., Chokephaibulkit, K.
10.1101/2022.12.16.22283601 — Posted: 2022-12-18
The effect of COVID-19 lockdowns on fertility in the Democratic Republic of the Congo
Feng, S., Kyomba, G., Mayaka, S. M., Grepin, K. A.
10.1101/2022.12.16.22283557 — Posted: 2022-12-18
Booster Vaccination with SARS-CoV-2 mRNA Vaccines and Myocarditis Risk in Adolescents and Young Adults: A Nordic Cohort Study of 8.9 Million Residents
Hviid, A., Nieminen, T., Pihlstrom, N., Gunnes, N., Dahl, J., Karlstad, O., Gulseth, H. L., Sunstrom, A., Husby, A., Hansen, J. V., Ljung, R., Hovi, P.
10.1101/2022.12.16.22283603 — Posted: 2022-12-18
Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Horby, P. W., Emberson, J. R., Basnyat, B., Campbell, M., Peto, L., Pessoa-Amorim, G., Staplin, N., Hamers, R. L., Amuasi, J., Nel, J., Kestelyn, E., Rawal, M., Jha, R. K., Phong, N. T., Samardi, U., Paudel, D., Thach, P. N., Nasronudin, N., Stratton, E., Mew, L., Sarkar, R., Baillie, J. K., Buch, M. H., Day, J. N., Faust, S. N., Jaki, T., Jeffery, K., Juszczak, E., Knight, M., Lim, W. S., Mafham, M., Montgomery, A., Mumford, A., Rowan, K., Thwaites, G., Haynes, R., Landray, M. J.
10.1101/2022.12.16.22283578 — Posted: 2022-12-17
Flattening the Curve is Imperative: When China Relaxes the Dynamic Zero COVID-19 Policy
Zhao, S., Sha, T., Xue, Y., Chen, H.
10.1101/2022.12.15.22283335 — Posted: 2022-12-17
Sustained reductions in life-threatening invasive bacterial diseases during the first two years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries participating in the IRIS Consortium
Shaw, D., Brueggemann, A. B.
10.1101/2022.12.16.22283251 — Posted: 2022-12-17
The Impact of Freeze-Thaw Cycles on the Integrity of SARS-COV-2 Viral Culture Fluids and Clinical Remnant Samples in Antigen or Nucleic Acid Testing
Hussain, H. N., Weeks, H., Zhou, D., Joseph, D., Lam, B., Xu, H., Zhang, C., Gregg, K., Zhou, W.
10.1101/2022.12.14.22282041 — Posted: 2022-12-16
Cholesterol and ceramide facilitate SARS-CoV-2 Spike protein-mediated membrane fusion
Niort, K., Dancourt, J., Boedec, E., Al Amir Dache, Z., Lavieu, G., Tareste, D.
10.1101/2022.12.16.520599 — Posted: 2022-12-16
Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.
Munoz Alia, M. A., Nace, R. A., Balakrishnan, B., Zhang, L., Packiriswamy, N., Singh, G., Warang, P., Mena, I., Narjari, R., Vandergaast, R., Garcia-Sastre, A., Schotsaert, M., Russell, S. J.
10.1101/2022.12.16.520799 — Posted: 2022-12-16
The H163A Mutation Unravels an Oxidized Conformation of the SARS-CoV-2 Main Protease and Opens a New Avenue for Anti-Viral Therapeutic Design
Tran, N., Dasari, S., Barwell, S., McLeod, M., Kalyaanamoorthy, S., Holyoak, T., Ganesan, A.
10.1101/2022.12.16.520794 — Posted: 2022-12-16

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).